Cancer Research Meeting Calendar Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spugnardi, M.
Right arrow Articles by Hoon, D. S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spugnardi, M.
Right arrow Articles by Hoon, D. S. B.
[Cancer Research 63, 1639-1643, April 1, 2003]
© 2003 American Association for Cancer Research

Molecular Biology and Genetics

Epigenetic Inactivation of RAS Association Domain Family Protein 1 (RASSF1A) in Malignant Cutaneous Melanoma1

Mia Spugnardi2, Stella Tommasi2, Reinhard Dammann, Gerd P. Pfeifer and Dave S. B. Hoon3

Department of Molecular Oncology, John Wayne Cancer Institute, Saint John’s Health Center, Santa Monica, California 90404 [M. S., D. S. B. H.]; Department of Biology, Beckman Research Institute, City of Hope Medical Center, Duarte, California 91010 [S. T., G. P. P.]; and AG Tumorgenetik der Medizinischen Fakultät, Martin-Luther-Universität Halle-Wittenberg, Halle/Saale, Germany [R. D.]

Recent findings have shown the inactivation of a Ras effector homologue gene referred to as the Ras association domain family 1 (RASSF1) gene, which is a potential human tumor suppressor gene located on chromosome 3p21.3. Hypermethylation of the CpG island promoter region of a major alternative transcript of this gene, RASSF1A, has been suggested to play a key role in pathogenesis of various carcinomas. There is limited analysis of inactivation of RASSF1A in tumors other than carcinomas. Hypermethylation of two regions of the RASSF1A CpG island was investigated in metastatic cutaneous melanomas using methylation-specific PCR; region 1 is located upstream, and region 2 is located within the first exon (1{alpha}) of the open reading frame of the RASSF1A transcript. Eleven melanoma cell lines and 44 melanoma tumors were examined. Methylation of RASSF1A CpG island promoter region 1 was detected in 7 (64%) cell lines and 18 (41%) tumors, and methylation of region 2 was detected in 9 (82%) cell lines and 22 (50%) tumors. Overall, RASSF1A gene hypermethylation was detected in 55% of the melanoma tumors. No methylation was detected in normal skin tissues or healthy donor lymphocytes. All cell lines that showed methylation at promoter region 1 were also methylated at promoter region 2. Hypermethylation of both CpG island regions correlated with no expression of the RASSF1A gene. RASSF1A transcripts could be reexpressed in cell lines after treatment with 5'-aza-2'-deoxycytidine. Our findings indicate that the RASSF1A gene is turned off in a significant number of melanomas and that CpG promoter region hypermethylation may play a role in the transcriptional inactivation of the RASSF1A gene in malignant melanoma.




This article has been cited by other articles:


Home page
 Genome ResHome page
Y. Koga, M. Pelizzola, E. Cheng, M. Krauthammer, M. Sznol, S. Ariyan, D. Narayan, A. M. Molinaro, R. Halaban, and S. M. Weissman
Genome-wide screen of promoter methylation identifies novel markers in melanoma
Genome Res., August 1, 2009; 19(8): 1462 - 1470.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Kitago, S. R. Martinez, T. Nakamura, M.-S. Sim, and D. S.B. Hoon
Regulation of RUNX3 Tumor Suppressor Gene Expression in Cutaneous Melanoma
Clin. Cancer Res., May 1, 2009; 15(9): 2988 - 2994.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Kitago, K. Koyanagi, T. Nakamura, Y. Goto, M. Faries, S. J. O'Day, D. L. Morton, S. Ferrone, and D. S.B. Hoon
mRNA Expression and BRAF Mutation in Circulating Melanoma Cells Isolated from Peripheral Blood with High Molecular Weight Melanoma-Associated Antigen-Specific Monoclonal Antibody Beads
Clin. Chem., April 1, 2009; 55(4): 757 - 764.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Tanemura, A. M. Terando, M.-S. Sim, A. Q. van Hoesel, M. F.G. de Maat, D. L. Morton, and D. S.B. Hoon
CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma
Clin. Cancer Res., March 1, 2009; 15(5): 1801 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. F.G. de Maat, C. J.H. van de Velde, M. P.J. van der Werff, H. Putter, N. Umetani, E. M. Klein-Kranenbarg, R. R. Turner, J. H. J.M. van Krieken, A. Bilchik, R. A.E.M. Tollenaar, et al.
Quantitative Analysis of Methylation of Genomic Loci in Early-Stage Rectal Cancer Predicts Distant Recurrence
J. Clin. Oncol., May 10, 2008; 26(14): 2327 - 2335.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
A P Moulin, G Clement, F T Bosman, L Zografos, and J Benhattar
Methylation of CpG island promoters in uveal melanoma
Br J Ophthalmol, February 1, 2008; 92(2): 281 - 285.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. F.G. de Maat, C. J.H. van de Velde, N. Umetani, P. de Heer, H. Putter, A. Q. van Hoesel, G. A. Meijer, N. C. van Grieken, P. J.K. Kuppen, A. J. Bilchik, et al.
Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer
J. Clin. Oncol., November 1, 2007; 25(31): 4887 - 4894.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. Merhavi, Y. Cohen, B. C. R. Avraham, S. Frenkel, I. Chowers, J. Pe'er, and N. Goldenberg-Cohen
Promoter Methylation Status of Multiple Genes in Uveal Melanoma
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4403 - 4406.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
H. Donninger, M. D. Vos, and G. J. Clark
The RASSF1A tumor suppressor
J. Cell Sci., September 15, 2007; 120(18): 3163 - 3172.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
M. F.G. de Maat, N. Umetani, E. Sunami, R. R. Turner, and D. S.B. Hoon
Assessment of Methylation Events during Colorectal Tumor Progression by Absolute Quantitative Analysis of Methylated Alleles
Mol. Cancer Res., May 1, 2007; 5(5): 461 - 471.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. Takeuchi, N. C. Greep, D. S. B. Hoon, A. E. Giuliano, N. M. Hansen, N. Umetani, and F. R. Singer
Hypermethylation of Adenosine Triphosphate-Binding Cassette Transporter Genes in Primary Hyperparathyroidism and Its Effect on Sestamibi Imaging
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1785 - 1790.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
W. Maat, P. A. van der Velden, C. Out-Luiting, M. Plug, A. Dirks-Mulder, M. J. Jager, and N. A. Gruis
Epigenetic Inactivation of RASSF1a in Uveal Melanoma
Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 486 - 490.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Muthusamy, S. Duraisamy, C. M. Bradbury, C. Hobbs, D. P. Curley, B. Nelson, and M. Bosenberg
Epigenetic Silencing of Novel Tumor Suppressors in Malignant Melanoma
Cancer Res., December 1, 2006; 66(23): 11187 - 11193.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J Kim, H A Reber, S M Dry, D Elashoff, S L Chen, N Umetani, M Kitago, O J Hines, K K Kazanjian, S Hiramatsu, et al.
Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins
Gut, November 1, 2006; 55(11): 1598 - 1605.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Mirmohammadsadegh, A. Marini, S. Nambiar, M. Hassan, A. Tannapfel, T. Ruzicka, and U. R. Hengge
Epigenetic Silencing of the PTEN Gene in Melanoma.
Cancer Res., July 1, 2006; 66(13): 6546 - 6552.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Mori, S. R. Martinez, S. J. O'Day, D. L. Morton, N. Umetani, M. Kitago, A. Tanemura, S. L. Nguyen, A. N. Tran, H.-J. Wang, et al.
Estrogen Receptor-{alpha} Methylation Predicts Melanoma Progression.
Cancer Res., July 1, 2006; 66(13): 6692 - 6698.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. Umetani, M. F.G. de Maat, E. Sunami, S. Hiramatsu, S. Martinez, and D. S.B. Hoon
Methylation of p16 and Ras Association Domain Family Protein 1a during Colorectal Malignant Transformation
Mol. Cancer Res., May 1, 2006; 4(5): 303 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. J. Reu, D. W. Leaman, R. R. Maitra, S. I. Bae, L. Cherkassky, M. W. Fox, D. R. Rempinski, N. Beaulieu, A. R. MacLeod, and E. C. Borden
Expression of RASSF1A, an Epigenetically Silenced Tumor Suppressor, Overcomes Resistance to Apoptosis Induction by Interferons.
Cancer Res., March 1, 2006; 66(5): 2785 - 2793.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Agathanggelou, W. N. Cooper, and F. Latif
Role of the Ras-Association Domain Family 1 Tumor Suppressor Gene in Human Cancers
Cancer Res., May 1, 2005; 65(9): 3497 - 3508.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Shinozaki, D. S.B. Hoon, A. E. Giuliano, N. M. Hansen, H.-J. Wang, R. Turner, and B. Taback
Distinct Hypermethylation Profile of Primary Breast Cancer Is Associated with Sentinel Lymph Node Metastasis
Clin. Cancer Res., March 15, 2005; 11(6): 2156 - 2162.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
K. K. Sra, M. Babb-Tarbox, S. Aboutalebi, P. Rady, G. L. Shipley, D. D. Dao, and S. K. Tyring
Molecular Diagnosis of Cutaneous Diseases
Arch Dermatol, February 1, 2005; 141(2): 225 - 241.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Tommasi, R. Dammann, Z. Zhang, Y. Wang, L. Liu, W. M. Tsark, S. P. Wilczynski, J. Li, M. You, and G. P. Pfeifer
Tumor Susceptibility of Rassf1a Knockout Mice
Cancer Res., January 1, 2005; 65(1): 92 - 98.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Umetani, H. Takeuchi, A. Fujimoto, M. Shinozaki, A. J. Bilchik, and D. S. B. Hoon
Epigenetic Inactivation of ID4 in Colorectal Carcinomas Correlates with Poor Differentiation and Unfavorable Prognosis
Clin. Cancer Res., November 15, 2004; 10(22): 7475 - 7483.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Fujimoto, H. Takeuchi, B. Taback, E. C. Hsueh, D. Elashoff, D. L. Morton, and D. S. B. Hoon
Allelic Imbalance of 12q22-23 Associated with APAF-1 Locus Correlates with Poor Disease Outcome in Cutaneous Melanoma
Cancer Res., March 15, 2004; 64(6): 2245 - 2250.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Shinozaki, A. Fujimoto, D. L. Morton, and D. S. B. Hoon
Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas
Clin. Cancer Res., March 1, 2004; 10(5): 1753 - 1757.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.